Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats

doi:10.3748/wjg.v12.i41.6639

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2828)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

344

HTML

2108

Figures (1-3)

182

Tables (1-4)

194

Sum=2828

Nov 7, 2006 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (18)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Nov 7, 2006; 12(41): 6639-6645
Published online Nov 7, 2006. doi: 10.3748/wjg.v12.i41.6639

Table 1 General characteristics of rats

Characteristics	Sham		BDL		P
	Placebo n = 9	V-PYRRO/NO n = 12	Placebo n = 12	V-PYRRO/NO n = 10
Initial body weight (g)	299 ± 34	274 ± 29	288 ± 56	293 ± 67	NS
Body weight gain (%)	33 ± 21	22 ± 9	14 ± 12^a	21 ± 17	0.04
Liver / body weight (%)	2.3 ± 0.4	2.8 ± 0.3	5.9 ± 1.5^a	5.6 ± 2.0^c	< 0.0001
Ascites score	0	0	0.3 ± 0.9	0	NS

^aP < 0.05 vs sham,

^cP < 0.05 vs V-PYRRO/NO sham; NS: Not significant.

Table 2 Liver and kidney serum function tests of rats

Parameter	Sham		BDL		P
	Placebo n = 9	V-PYRRO/NO n = 12	Placebo n = 12	V-PYRRO/NO n = 10
Urea (mmol/L)	10.2 ± 2.1	7.9 ± 1.7	9.2 ± 1.6	9.5 ± 2.7	NS
Creatinine (μmol/L)	77 ± 25	63 ± 24	66 ± 11	73 ± 18	NS
AST (UI/L)	172 ± 52	123 ± 60	1150 ± 1480^a	1164 ± 1349^c	< 0.0001
ALT (UI/L)	48 ± 18	55 ± 36	88 ± 47	82 ± 20	NS
Alkaline phosphatases (UI/L)	160 ± 103	148 ± 80	380 ± 197^a	367 ± 141^c	< 0.001
Bilirubin (μmol/L)	1.0 ± 0.0	1.3 ± 0.5	117.0 ± 22.0^a	101.0 ± 30.0^c	< 0.0001

^aP < 0.05 vs sham placebo,

^cP < 0.05 vs sham V-PYRRO/NO; NS: Not significant.

Table 3 Hemodynamic data of rats

	Sham		BDL		P
	Placebo n = 9	V-PYRRO/NO n = 12	Placebo n = 12	V-PYRRO/NO n = 10
MAP (mm Hg)	119 ± 7	113 ± 11	104 ± 8^a	98 ± 13^b	< 0.001
Heart rate (beat/min)	441 ± 29	428 ± 44	411 ± 29	422 ± 26	NS
Cardiac index (mL/min .100 g)	14 ± 5	15 ± 4	39 ± 11^a	33 ± 6^a^c	< 0.0001
SVR (dyn.s.cm⁵.100 g¹.10³)	782 ± 355	636 ± 184	236 ± 89^a	248 ± 78^c	< 0.0001
Portal pressure (mmHg)	9.2 ± 0.8	8.0 ± 1.2	16.3 ± 2.2^a	11.9 ± 2.7^a^c^e	< 0.0001
SRS BF (mL/min)	0.22 ± 0.08	0.31 ± 0.12	1.33 ± 1.34^a	0.42 ± 0.22^e	0.007

^aP < 0.05 vs Sham,

^cP < 0.05 vs sham V-PYRRO/NO,

^eP < 0.05 vs BDL placebo. MAP: Mean arterial pressure, SRS BF: Spleno-renal shunt blood flow; SVR: Systemic vascular resistance; NS: Not significant.

Table 4 Liver fibrosis of rats

	Sham		BDL		P
	Placebo n = 9	V-PYRRO/NO n = 12	Placebo n = 12	V-PYRRO/NO n = 10
Area (%)	2.5 ± 0.5	3.1 ± 0.8	12.1 ± 4.3^a	8.4 ± 3.6^c^e	< 0.0001
Liver hydroxyproline (μg/g protein)	164 ± 26	171 ± 49	381 ± 88^a	268 ± 83^c^e	< 0.0001

^aP < 0.05 vs Sham,

^cP < 0.05 vs sham V-PYRRO/NO,

^eP < 0.05 vs BDL placebo.

Citation: Moal F, Veal N, Vuillemin E, Barrière E, Wang J, Fizanne L, Oberti F, Douay O, Gallois Y, Bonnefont-Rousselot D, Rousselet MC, Calès P. Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRRO/NO in bile duct ligated rats. World J Gastroenterol 2006; 12(41): 6639-6645
URL: https://www.wjgnet.com/1007-9327/full/v12/i41/6639.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i41.6639